Comparison of treatment modalities in pancreatic pseudocyst: A population based study

Table 2 Specific comorbidities of the study cohort, n (%)

	Percutaneous	Laparoscopic	Surgical	P value
	n = 347	n = 248	n = 107
Acute myocardial infarction	15 (4.3)	8 (3.2)	5 (4.7)	0.74
Congestive heart failure	31 (8.9)	19 (7.7)	4 (3.7)	0.21
Peripheral vascular disease	15 (4.3)	7 (2.8)	3 (2.8)	0.56
Cerebrovascular disease	6 (1.7)	3 (1.2)	1 (0.9)	0.78
Dementia	2 (0.6)	3 (1.2)	0 (0.0)	0.42
Chronic obstructive pulmonary disease	58 (16.7)	43 (17.3)	16 (15.0)	0.86
Rheumatoid disease	11 (3.2)	3 (1.2)	0 (0.0)	0.07
Peptic ulcer disease	10 (2.9)	13 (5.2)	3 (2.8)	0.28
Mild liver disease	52 (15.0)	36 (14.5)	9 (8.4)	0.21
Diabetes without complications	105 (30.3)	61 (24.6)	32 (29.9)	0.29
Diabetes with complications	12 (3.5)	11 (4.4)	5 (4.7)	0.77
Hemiplegia or paraplegia	3 (0.9)	0 (0.0)	0 (0.0)	0.21
Renal disease	33 (9.5)	24 (9.7)	4 (3.7)	0.14
Cancer (any malignancy)	15 (4.3)	6 (2.4)	4 (3.7)	0.46
Moderate or severe liver disease	10 (2.9)	17 (6.9)	7 (6.5)	0.06
Metastatic solid tumour	6 (1.7)	2 (0.8)	0 (0.0)	0.28
AIDS/HIV	2 (0.6)	1 (0.4)	0 (0.0)	0.72